Altria's Investment in Juul Valued at $450 Million

Aug.02.2022
Altria's Investment in Juul Valued at $450 Million
Altria's 35% stake in Juul, the leading e-cigarette manufacturer, has decreased in value by 95% due to increasing safety concerns.

Juul became the global leader in electronic cigarette manufacturing in 2018, with its products gaining widespread popularity. Virginia-based tobacco brand Altria did not want to miss out on the opportunity presented by the rapidly growing e-cigarette market and acquired a 35% stake in Juul for 12.8% of the price. At the time, Altria firmly believed that e-cigarettes represented the future of tobacco use worldwide, and Juul was leading the way towards this promising future.


However, the reality is quite different. Recently, reports claiming that electronic cigarettes are just as dangerous as traditional smoking have dampened enthusiasm for the market, sending shockwaves throughout the entire industry. Even Juul, once the world's most valuable e-cigarette company, has seen its valuation drop following concerns raised by the FDA about the safety of its products, despite a recent investment from Altria.


Tobacco company Altria's investment in Juul is now valued at $450 million, less than 5% of the e-cigarette maker's 2018 valuation. Earlier this year, Altria lowered its valuation of Juul to $1.6 billion as the US Food and Drug Administration began reviewing Juul's products. In its Q2 earnings report, Altria further reduced the valuation by $1.2 billion, putting the new value at $450 million. Despite the drastic reduction, Altria says it has no plans to work with Juul and will honor its original agreement not to launch any new e-cigarette products or invest in other e-cigarette companies. "We made the decision not to make any different decisions," said Altria CEO Billy Gifford. "We believe the right decision at this point in time is to maintain noncompetition.


The rapid decline in Juul's valuation is due to the FDA's decision last month to ban Juul e-cigarettes, as the company failed to provide key information about its nicotine formula. This surprised many as the FDA has approved many similar products. While Juul received criticism from a federal court to continue selling its products, the FDA has re-examined the company's application and frozen its ban. This means that the future of Juul's products remains uncertain in the foreseeable future.


The FDA's decision stems from recent studies that indicate e-cigarettes are harmful to users and pressure from advocacy groups who believe these products are just as bad as traditional tobacco products. Therefore, the FDA is working to eliminate products that do not help smokers quit. Juul's various flavors and brightly colored packaging are attractive to non-smokers. Aside from its valuation, Juul's current issues have also led to a nearly 60% decrease in Altria's earnings to 49 cents per share. This has caused a 6% decrease in quarterly revenue to around $6.5 billion. Altria is the largest cigarette manufacturer in the US and, as smoking rates decline, the company is fighting hard in the Juul and future e-cigarette market.


This article is compiled from third-party information and is only for industry exchange and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot verify the truthfulness or accuracy of the content. The translation of this article is intended for industry-related discussions and research purposes only.


Due to limitations in translation capabilities, the translated article may not express the original meaning accurately. Please refer to the original article for accuracy.


2FIRSTS aligns completely with the Chinese government's views and positions on all domestic, Hong Kong, Macau, Taiwan, and international matters.


The compilation of information belongs to the original media outlet and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Vaping prevalence in Great Britain edged down to 9.9% in 2025 from 10.0% in 2024, with the number of adult users holding at approximately 5.4 million for a second consecutive year, according to the Office for National Statistics (ONS). E-cigarette use had risen from 6.4% in 2020 to 10.0% in 2024, when it exceeded cigarette smoking prevalence for the first time. Cigarette smoking continued to decline to 8.7% in 2025, widening the gap to 1.2 percentage points. Daily vaping declined slightly, while usage among adults aged 25–34 increased despite falling rates in other age groups.
DATA
Oct.14
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
DOJO officially launched the BLAST7K Fresh on September 17, 2026, introducing a UK-market prefilled pod product with 6ml of e-liquid and a manufacturer-rated capacity of up to 7,000 puffs. The device features a 1000mAh rechargeable battery, the INSTA-JUICED structure and COREX BLAST dual-mesh technology, while retaining compatibility with existing BLAST pods. The launch comes less than two weeks before the UK's Vaping Products Duty takes effect on October 1. At the new duty rate, 6ml of vaping liquid would correspond to £1.32 in VPD. DOJO has not stated that the product's 6ml format was designed in response to the new duty.
Sep.20
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
Product | Juul Labs Launches Upgraded JUUL2 Kit in UK With Four Pods at £9.99 and USB-C Charging
Product | Juul Labs Launches Upgraded JUUL2 Kit in UK With Four Pods at £9.99 and USB-C Charging
Juul Labs UK has introduced an upgraded JUUL2 Starter Kit for the UK market in October 2026, retaining a recommended retail price of £9.99 while doubling the number of included pods from two to four. The kit contains Crisp Menthol, Virginia Tobacco, Mango and Watermelon pods. The updated device replaces the previous proprietary charging dock with a USB-C port and offers longer battery life. The kit also features reduced packaging and retains a two-year limited warranty. Distribution is scheduled through major UK retailers, wholesalers, convenience stores and the JUUL UK website.
product
Oct.15
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
The European Patent Office (EPO) published an appeal decision on November 17, 2026, revoking Philip Morris Products S.A.'s European nicotine pouch patent EP 3773494, covering a formulation involving free-base nicotine, ion-exchange resin and a water content of at least 15%. The decision followed an opposition and appeal brought by British American Tobacco (BAT) entity Nicoventures Trading Limited. Philip Morris withdrew its approval of the patent text during the appeal, leading the EPO to revoke the patent. A separate European patent, EP 3809884, covering the distribution of nicotine between a pouch membrane and its internal composition, had been revoked on September 24 following a challenge from another BAT entity. The patents share a 2019 priority basis, while related European divisional applications also exist.
company
Nov.18 by 2Firsts Perspectives
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23